Hematologic Malignancies Diagnosed in the Context of Campaign: A Report of Two Cases

Medicina (Lithuania)

58, 874

DOI: 10.3390/medicina58070874

Citation Report

#	Article	IF	Citations
1	Reply to Çınar et al. Comment on "Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874― Medicina (Lithuania), 2022, 58, 1576.	2.0	0
2	Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874. Medicina (Lithuania), 2022, 58, 1575.	2.0	2
3	Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature. Medicina (Lithuania), 2023, 59, 157.	2.0	7
4	Ph-Positive B-Cell Acute Lymphoblastic Leukemia Occurring after Receipt of Bivalent SARS-CoV-2 mRNA Vaccine Booster: A Case Report. Medicina (Lithuania), 2023, 59, 627.	2.0	1
5	mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues. International Journal of Molecular Sciences, 2023, 24, 10514.	4.1	6
6	B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: A case report. Frontiers in Oncology, 0, 13 , .	2.8	2
8	Kaempferol: A Review of Current Evidence of Its Antiviral Potential. International Journal of Molecular Sciences, 2023, 24, 16299.	4.1	4
9	COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. Cureus, 2024, , .	0.5	2